MIT chemical engineers have developed a new sensor that lets them see inside cancer cells and determine whether the cells are responding to a particular type of chemotherapy drug.
The sensors, which detect hydrogen peroxide inside human cells, could help researchers identify new cancer drugs that boost levels of hydrogen peroxide, which induces programmed cell death. The sensors could also be adapted to screen individual patients’ tumors to predict whether such drugs would be effective against them.
“The same therapy isn’t going to work against all tumors,” says Hadley Sikes, an associate professor of chemical engineering at MIT. “Currently there’s a real dearth of quantitative, chemically specific tools to be able to measure the changes that occur in tumor cells versus normal cells in response to drug treatment.”
Sikes is the senior author of the study, which appears in the Aug. 7 issue of Nature Communications. The paper’s first author is graduate student Troy Langford; other authors are former graduate students Beijing Huang and Joseph Lim and graduate student Sun Jin Moon.
Tracking hydrogen peroxide
Cancer cells often have mutations that cause their metabolism to go awry and produce abnormally high fluxes of hydrogen peroxide. When too much of the molecule is produced, it can damage cells, so cancer cells become highly dependent on antioxidant systems that remove hydrogen peroxide from cells.
Drugs that target this vulnerability, which are known as “redox drugs,” can work by either disabling the antioxidant systems or further boosting production of hydrogen peroxide. Many such drugs have entered clinical trials, with mixed results.
“One of the problems is that the clinical trials usually find that they work for some patients and they don’t work for other patients,” Sikes says. “We really need tools to be able to do more well-designed trials where we figure out which patients are going to respond to this approach and which aren’t, so more of these drugs can be approved.”
To help move toward that goal, Sikes set out to design a sensor that could sensitively detect hydrogen peroxide inside human cells, allowing scientists to measure a cell’s response to such drugs.
Existing hydrogen peroxide sensors are based on proteins called transcription factors, taken from microbes and engineered to fluoresce when they react with hydrogen peroxide. Sikes and her colleagues tried to use these in human cells but found that they were not sensitive in the range of hydrogen peroxide they were trying to detect, which led them to seek human proteins that could perform the task.
Through studies of the network of human proteins that become oxidized with increasing hydrogen peroxide, the researchers identified an enzyme called peroxiredoxin that dominates most human cells’ reactions with the molecule. One of this enzyme’s many functions is sensing changes in hydrogen peroxide levels.
Langford then modified the protein by adding two fluorescent molecules to it — a green fluorescent protein at one end and a red fluorescent protein at the other end. When the sensor reacts with hydrogen peroxide, its shape changes, bringing the two fluorescent proteins closer together. The researchers can detect whether this shift has occurred by shining green light onto the cells: If no hydrogen peroxide has been detected, the glow remains green; if hydrogen peroxide is present, the sensor glows red instead.
The researchers tested their new sensor in two types of human cancer cells: one set that they knew was susceptible to a redox drug called piperlongumine, and another that they knew was not susceptible. The sensor revealed that hydrogen peroxide levels were unchanged in the resistant cells but went up in the susceptible cells, as the researchers expected.
Sikes envisions two major uses for this sensor. One is to screen libraries of existing drugs, or compounds that could potentially be used as drugs, to determine if they have the desired effect of increasing hydrogen peroxide concentration in cancer cells. Another potential use is to screen patients before they receive such drugs, to see if the drugs will be successful against each patient’s tumor. Sikes is now pursuing both of these approaches.
“You have to know which cancer drugs work in this way, and then which tumors are going to respond,” she says. “Those are two separate but related problems that both need to be solved for this approach to have practical impact in the clinic.”
The Latest on: Cancer therapy
via Google News
The Latest on: Cancer therapy
- AMERICAN AIRLINES PUSHING CANCER RESEARCH TO NEW HEIGHTS WITH FUNDRAISING CAMPAIGNon August 1, 2022 at 8:58 pm
American Airlines, in collaboration with Stand Up To Cancer (SU2C) and Emmy, Grammy and Golden Globe-nominated actress, singer and songwriter Mandy Moore, is launching its annual campaign to raise ...
- UCR researcher employs Actor-Network Theory to open black boxes in breast cancer survivorship careon August 1, 2022 at 5:26 pm
Today, many women diagnosed with breast cancer live long after completing their cancer treatments and have post-treatment health and information needs.
- First patient to try revolutionary new cancer therapy is in remissionon August 1, 2022 at 2:52 pm
Researchers managed to create a new cancer therapy that has proven effective, pushing a patient's cancer into remission for over a full year.
- Study examines 'black boxing' in breast cancer survivorship careon August 1, 2022 at 2:18 pm
Today, many women diagnosed with breast cancer live long after completing their cancer treatments and have post-treatment health and information needs. Unfortunately, across healthcare systems, ...
- 2 more people have been 'cured' of HIV — 1 man thanks to cancer treatment, and 1 woman who mysteriously developed natural control over the viruson August 1, 2022 at 12:33 pm
Two more patients were announced functionally "cured" of HIV during AIDS 2022. One had cancer, the other has naturally controlled the virus for years.
- New Lung Cancer Treatment Optionson August 1, 2022 at 12:03 pm
Doctor of Internal Medicine and lung cancer survivor, Sydney Barned, and fellow lung cancer survivor, Brandi Bryant, tell HRS about new lung cancer treatment options.
- FDA puts clinical hold on Beam Theraputics’ cancer therapyon August 1, 2022 at 7:46 am
The FDA has placed a hold on U.S. biopharma company Beam Therapeutics' Investigational New Drug (IND) application.
- Novel targeted therapy could be effective treatment option for deadly childhood canceron July 27, 2022 at 5:00 pm
New research from VCU Massey Cancer Center — published this week in Cell Reports — demonstrated that a novel targeted therapy could be an effective treatment option for a deadly pediatric cancer known ...
- Prostate Cancer Treatment May Raise Heart Riskson July 27, 2022 at 8:47 am
Hormone therapy is a common treatment option for prostate cancer, but it may increase the risk of death from heart disease, especially in older men, a new study finds. Dr. William Dahut, a prostate ...
via Bing News